Log in

DARA Biosciences Stock Price, Forecast & Analysis (NASDAQ:DARA)

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.32
0.00 (0.00 %)
(As of 06/27/2019)
Add
Today's Range
$0.31
Now: $0.32
$0.32
50-Day Range
$0.32
MA: $0.32
$0.33
52-Week Range
$0.67
Now: $0.32
$1.05
Volume12,500 shs
Average Volume118,843 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company's primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:DARA
CUSIPN/A
Phone+1-816-9147027

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive DARA News and Ratings via Email

Sign-up to receive the latest news and ratings for DARA and its competitors with MarketBeat's FREE daily newsletter.


DARA Biosciences (NASDAQ:DARA) Frequently Asked Questions

What is DARA Biosciences' stock symbol?

DARA Biosciences trades on the NASDAQ under the ticker symbol "DARA."

How were DARA Biosciences' earnings last quarter?

DARA Biosciences Inc (NASDAQ:DARA) released its earnings results on Monday, November, 2nd. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.14). The specialty pharmaceutical company earned $1.18 million during the quarter, compared to the consensus estimate of $0.83 million. View DARA Biosciences' Earnings History.

Has DARA Biosciences been receiving favorable news coverage?

Headlines about DARA stock have been trending somewhat negative on Friday, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. DARA Biosciences earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for DARA Biosciences.

What other stocks do shareholders of DARA Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DARA Biosciences investors own include Castleton Technology (CTP), Richland Resources (RLD), THOR MINI/PAR VTG FPD 0.0001 (THR), Global Invacom Group (GINV), Legendary Investments (LEG), Octagonal (OCT), iPass (IPAS), Clontarf Energy (CLON), Starcom (STAR) and AEterna Zentaris (AEZS).

What is DARA Biosciences' stock price today?

One share of DARA stock can currently be purchased for approximately $0.32.

What is DARA Biosciences' official website?

The official website for DARA Biosciences is http://www.darabiosciences.com/.

How can I contact DARA Biosciences?

DARA Biosciences' mailing address is 8601 Six Forks Rd Ste 160, RALEIGH, NC 27615-2965, United States. The specialty pharmaceutical company can be reached via phone at +1-816-9147027.


MarketBeat Community Rating for DARA Biosciences (NASDAQ DARA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  104 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  183
MarketBeat's community ratings are surveys of what our community members think about DARA Biosciences and other stocks. Vote "Outperform" if you believe DARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DARA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel